Cramer‘s Analyst Says Eli Lilly’s GLP-1 Stock Rally Has Years Left to Run

WikiBit|2026-08-11

Абстракт:On Mad Money, Jim Cramer and analyst Jeff Marks said Eli Lilly remains a top momentum stock with a multi-year runway, not a short-term trade, especially as GLP-1 sales peak toward the end of the decade. The drugmaker‘s blowout second quarter supported that view: revenue rose 48% to $23 billion, volume jumped 60%, and management raised full-year guidance to $85–87 billion. Mounjaro sales climbed 91% to $9.9 billion, while Zepbound’s U.S. revenue grew 44%. International revenue surged 80% to $8.6 billion despite a 36% price decline after Mounjaro joined Chinas NRDL, widening access. Morgan Stanley projects the global obesity and diabetes drug market will nearly double to $190 billion by 2035.

Eli Lilly (LLY) posted a blowout quarter, and Mad Money says the GLP-1 drugmakers stock story is far from over.

Jim Cramer and CNBC analyst Jeff Marks called Eli Lilly and Nvidia top momentum stocks.

Sponsored

Why Eli Lillys GLP-1 Stock Still Has Room to Run

The comment came during a viewer question about how price targets get set. Cramer raised Eli Lilly and Nvidias runs specifically when asking about the process.

Marks, the CNBC Investing Clubs portfolio analyst, said stocks like these need a longer time horizon than most.

“Stocks like that you also have to look out years out in advance, too. Especially in the case of Eli Lilly, where it‘s more of towards the end of the decade is where it’s GLP-1 sales.”

— Jeff Marks, CNBC Investing Club portfolio analyst, on Mad Money

Eli Lillys second-quarter results back that framing. Revenue hit $23 billion, up 48% year over year. A 60% jump in sales volume offset a 13% drop in realized prices.

Management raised full-year revenue guidance to a range of $85 billion to $87 billion. Mounjaro sales rose 91% to $9.9 billion worldwide. Zepbounds U.S. revenue grew 44% to $4.9 billion.

Sponsored

Cramers other 2026 stock picks lean on similarly durable, multi-year themes rather than short-term trades.

Global GLP-1 Demand Is Still Early

Eli Lillys international business is growing even faster than its U.S. business. Revenue outside the U.S. jumped 80% to $8.6 billion in the quarter, while volume surged 113%.

Eli Lilly is up 88% in the last 12 months. Image Source: Trading View

That growth came even as prices outside the U.S. fell 36%. The decline followed Mounjaro‘s addition to China’s National Reimbursement Drug List (NRDL), a program covering drug costs under public insurance.

Lower prices widen access for millions of new patients, even as they compress near-term margins. Morgan Stanley expects the global obesity and diabetes drug market to nearly double by 2035.

The firm projects $190 billion in sales, up from $79 billion in 2025. Oral GLP-1 pills and expanding insurance coverage are the main drivers behind that forecast.

For Marks and Cramer, runway and scale are why Eli Lillys momentum looks built for years, not quarters.

Отказ от ответственности

Мнения в этой статье отражают только личное мнение автора и не являются советом по инвестированию для этой платформы. Эта платформа не гарантирует точность, полноту и актуальность информации о статье, а также не несет ответственности за любые убытки, вызванные использованием или надежностью информации о статье.